ARTHQ (Arch Therapeutics) Total Liabilities: $13.96 Mil (As of Jun. 2024)


ARTHQ Arch Therapeutics Inc ARTHQ
12 GF Score
Price $0.00
View Full Analysis

What is Arch Therapeutics Total Liabilities?

Arch Therapeutics ARTHQ -99.00% 12 Total Liabilities is $13.96 Mil as of Jun. 2024. GuruFocus rates ARTHQ with a GF Score™ of 12/100.

Arch Therapeutics's Total Liabilities for the quarter that ended in Jun. 2024 was $13.96 Mil.

Arch Therapeutics's quarterly Total Liabilities increased from Dec. 2023 ($11.40 Mil) to Mar. 2024 ($12.42 Mil) and increased from Mar. 2024 ($12.42 Mil) to Jun. 2024 ($13.96 Mil).

Arch Therapeutics's annual Total Liabilities increased from Sep. 2021 ($4.70 Mil) to Sep. 2022 ($6.80 Mil) and increased from Sep. 2022 ($6.80 Mil) to Sep. 2023 ($9.47 Mil).

Arch Therapeutics Total Liabilities Historical Data

* Premium members only.

The historical data trend for Arch Therapeutics's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Arch Therapeutics Total Liabilities Chart

Arch Therapeutics Annual Data
Trend Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.71 3.65 4.70 6.80 9.47

Arch Therapeutics Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9.58 9.47 11.40 12.42 13.96
ARTHQ
12GF Score
Arch Therapeutics Inc ARTHQ
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Arch Therapeutics Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Arch Therapeutics's Total Liabilities for the fiscal year that ended in Sep. 2023 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=9.466+(0+0
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=9.47

Total Liabilities=Total Assets (A: Sep. 2023 )-Total Equity (A: Sep. 2023 )
=1.958--7.508
=9.47

Arch Therapeutics's Total Liabilities for the quarter that ended in Jun. 2024 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=13.958+(0+0
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=13.96

Total Liabilities=Total Assets (Q: Jun. 2024 )-Total Equity (Q: Jun. 2024 )
=1.398--12.561
=13.96

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of $13.96 Mil mean?
Arch Therapeutics (ARTHQ) has a Total Liabilities of $13.96 Mil as of Jun. 2024. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Arch Therapeutics and its competitors.
Is Arch Therapeutics' Total Liabilities too high?
Arch Therapeutics' current Total Liabilities is $13.96 Mil. Overall, Arch Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Arch Therapeutics' Total Liabilities compare to GRTSQ and MTEM?
Arch Therapeutics' Total Liabilities of $13.96 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Arch Therapeutics and its competitors. Arch Therapeutics's current Total Liabilities is $13.96 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Arch Therapeutics stock overvalued right now?
Arch Therapeutics (ARTHQ) has a current Total Liabilities of $13.96 Mil. The current Total Liabilities is $13.96 Mil. Arch Therapeutics' overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Arch Therapeutics (ARTHQ), the current Total Liabilities is $13.96 Mil as of Jun. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Arch Therapeutics Business Description

Address 235 Walnut Street, Suite 6, Framingham, MA, USA, 01702
Arch Therapeutics Inc is a development-stage biotechnology company. It focuses on developing products that manage surgery and interventional care faster and safer by using a novel approach to stop bleeding, control leaking, and provide other advantages during surgery and trauma care. The company's primary product candidate, collectively known as the AC5 Devices (AC5), is designed to achieve hemostasis in surgical procedures. The company operates its business operations in the United States.
12GF Score

Get the complete analysis for ARTHQ

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price